Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...

A new phase 2 clinical trial suggests that a chemotherapy-free, minimal residual disease (MRD)–driven treatment strategy may offer durable remissions and the possibility of time-limited therapy for ...

Oxidative stress is caused by an imbalance between the production of reactive oxygen species (ROS) and the ability of the ...

The adequate supplementation of vitamin D3 to food-producing animals is of crucial importance due to its multiple benefits in bone and muscle development as well as in immune response modulation. This ...

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...

By Dr. Sanchari Sinha Dutta, Ph.D. A microbial metabolite long linked to cardiovascular risk emerges as a surprising ally ...

Amyotrophic lateral sclerosis (ALS) affects nerve cells in the brain and spinal cord. The authors' approach to use genetic code expansion to tag two ALS proteins associated with stress granules has ...

Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...

The bacterium that causes TB can hide in liver cells called hepatocytes, and reprogram their metabolism for its own benefit.

Background CFTR modulators have transformed cystic fibrosis (CF) treatment, but individual responses vary even among patients with identical CFTR genotypes. This underscores the need for predictive ...